BeyondSpring Inc. announced on July 07, 2025, the publication of a human clinical study in *Med (Cell Press)*, dated June 27, 2025. The study demonstrated that Plinabulin, when combined with radiation and a checkpoint inhibitor, induces dendritic cell (DC) maturation and elicits tumor responses in patients across multiple cancer types who had failed prior immune checkpoint inhibitor (ICI) therapy.
The investigator-initiated Phase 1 translational trial (NCT04902040) also identified a potential biomarker, baseline GEF-H1 immune signature, which may enable patient pre-selection and clinical response prediction. The study observed the best responses in non-small cell lung cancer, head and neck squamous cell carcinoma, and Hodgkin lymphoma.
This publication provides scientific validation for Plinabulin's unique mechanism of action in activating the immune system to overcome acquired ICI resistance. The findings are considered clinically promising, particularly given the durability of responses observed in some heavily pretreated patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.